{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:13:59Z","timestamp":1788012839372,"version":"build-2784847793"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T00:00:00Z","timestamp":1254873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T00:00:00Z","timestamp":1254873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"abstract":"<jats:p>Background: While interferon (IFN) is known for its immunoregulatory properties, it has also been shown to induce autoimmune disorders such as lupusery-thematosus, hypothyroidism, antiphospholipid syndrome and, recently, bullous pemphigus-like eruptions. Objective: The purpose of this study was to determine the percentage of antibodies against epidermis induced by IFN-\u03b1 therapy, as detected by indirect immunofluorescence and Western blotting (WB). Method: We have studied the sera of 47 patients treated with low doses of IFN-\u03b12a for malignant melanoma or cutaneous T cell lymphoma for a period of 12 months. These sera were tested by standard IIF and WB. Results: 32% of patient sera were positive after 6 months of treatment. Antibodies against epidennis were most often of the pemphigus type as confirmed by WB. Two types of labeling were noted for anti-basement membrane antibodies: basal cytoplasmic pattern in 4 sera and along the dermal side of the basal keratinocytes in 2 sera. Conclusion: This study brings biological arguments to confirm the direct role of IFN-\u03b1 in the development of pemphigus-like eruption, and emphasizes the need for clinical follow-up of patients treated with IFN-\u03b1 over a long period of time.<\/jats:p>","DOI":"10.1159\/000246315","type":"journal-article","created":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T07:08:20Z","timestamp":1254899300000},"page":"50-55","source":"Crossref","is-referenced-by-count":54,"title":["Long-Term Interferon-Alpha Therapy Induces Autoantibodies against Epidermis"],"prefix":"10.1159","author":[{"given":"M.","family":"Fleischmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"C\u00e9l\u00e9rier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Litoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2009,10,7]]},"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/246315","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000246315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:15:10Z","timestamp":1777540510000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000246315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,7]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000246315","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,7]]}}}